We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Rua Life Sciences Plc | LSE:RUA | London | Ordinary Share | GB0033360586 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.50 | 4.88% | 10.75 | 10.50 | 11.00 | 10.75 | 10.25 | 10.25 | 344,898 | 11:00:24 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Plastics,resins,elastomers | 2.18M | -2M | -0.0323 | -3.33 | 6.67M |
Date | Subject | Author | Discuss |
---|---|---|---|
29/12/2021 12:49 | Looks like someone is dumping stock….either it is a distressed big holder or may even be an II colluding with a big player to facilitate cheap takeover! This is the most likely explanation. Uncertainty around FDA 510k is not the entire cause of this! | aykon | |
29/12/2021 12:45 | They need to put out a release with total upfront honesty warts and all. The share price is more likely to recover/stabilise if they lay it all out so investors can stop speculating. Too much uncertainty and if they don't address it they'll be raising at a much lower price unfortunately. Get that release out and get it done | mikeh30 | |
29/12/2021 12:08 | PS looks like dogsh*te capital are still on our side after buying in at 130, so their unrealised loss is bigger than mine lol. | the_real_mr_big | |
29/12/2021 12:07 | As long as I'm not looking at the sp, I'm getting more optimistic. From a glimpse of the FDA 510k clinical studies presentation: - 10-15% of 510k applications require clinical studies. Looks like we're just 1-in-10 cases. Big de-stresser for me, as I thought our problems were more along the lines of inability to use 510k route. - Size of clinical studies dictated by the ability of bench & animal testing to answer questions. Hopefully, we just need a few extra data points satisfied, but wtfdik. Sitting on a huge loss here, but I can see this bouncing back up on a slither of good news. Until then I'll keep on holding on to this falling knife until I bleed dry. Bring on the FDA response in January. £15m mcap with £4m in cash and increasing revenues seems like the time to top up. Be greedy when everyone's planting trees, or whatever it was that Buffy said. | the_real_mr_big | |
29/12/2021 12:00 | Uncertainty and sentiment trumps everything else on illiquid AIM stocks unfortunately | mikeh30 | |
29/12/2021 11:31 | Come on. £15m mcap and it's falling. Seriously? | the_real_mr_big | |
23/12/2021 07:57 | Buywell asks has Buywell ever spotted an overvalued share Before it has collapsed. Buywell needs to ask Buywell why is investing easy with benefit of hindsight. | amt | |
22/12/2021 12:05 | The latest recruits came at the perfect time. The CFO has been through this before. The reg and clinical affairs chap arrived 6 weeks too late, but at least we can benefit from his experience. At current levels an opportunistic approach is an obvious risk. But if they get the new strategy right, with, say a £m strategic investment in new shares from an industry partner, all the angst will dissipate overnight. I did not buy the shares for the grafts or the patches. I bought for the massive heart-valve IP value and the Elasteon enabled disruption as the end of using animal derived material inevitably arrives. | greedy rooster | |
22/12/2021 10:09 | Amati dumping. This is bad. | the_real_mr_big | |
22/12/2021 07:24 | POST REMOVED | buywell3 | |
22/12/2021 06:40 | POST REMOVED | buywell3 | |
21/12/2021 08:34 | Well what can one say that has already hasn't been said.The fact is unless the board buy shares why should we investors ! | cocker | |
21/12/2021 01:08 | POST REMOVED | buywell3 | |
20/12/2021 21:36 | POST REMOVED | buywell3 | |
20/12/2021 16:42 | We didn't need to evolve into a large company - the 510k would have provided new cash for more R&D and increased the value of the graft business to be sold off. Anyway, nice to see some recovery. Has anyone managed a top up in the 60s? I only managed mid 70s. | the_real_mr_big | |
20/12/2021 13:16 | I’m still in but not sure that there will be any more video presentations. | semper vigilans | |
20/12/2021 09:55 | I still think that most investors don’t realise that this is essentially an R&D company (and with licensing rights to Elasteon). It is never going to evolve into a major graft company! The way the last update (last week£ has been structured does suggest to me that they have laid the stall to attract buyers for some part(s) of the company. However, this is my personal opinion of how I perceive it. | aykon | |
20/12/2021 09:21 | That’s very baa.baa..baar..baric Mr Big!!! | aykon | |
20/12/2021 09:10 | Yep. Packed onto a trailer, transported all the way up to Aberdeen and f.cked deep and hard. | the_real_mr_big | |
20/12/2021 09:04 | Just can’t get away from sheep references on this thread! | bones | |
20/12/2021 09:00 | Looks like a lot of PIs that panic sold have been well and truly fleeced!! | aykon | |
20/12/2021 08:54 | Being optimistic. Won't happen any time soon. The only problem with RUA now is the long delay before commercialising grafts. 18 months perhaps? That's too long for many PIs but nothing for IIs, so I'd expect a transfer of stock from PI to II hands. Looks like the share price chart has got a morning stiffy. Long may it continue. | the_real_mr_big | |
20/12/2021 07:33 | If directors aren't buying at these levels why should we!. Only excuse is in talks to sell something, or is that me being optimistic! | cocker | |
20/12/2021 02:35 | POST REMOVED | buywell3 | |
20/12/2021 00:10 | Oh my, he's copypasting charts now. Could it be that some II wants cheap shares and is paying this schmuck overtime for working on a Sunday? | the_real_mr_big |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions